Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study
Abstract
No effective pharmacological or non-pharmacological interventions exist for patients with long COVID. We aimed to describe recovery 1 year after hospital discharge for COVID-19, identify factors associated with patient-perceived recovery, and identify potential therapeutic targets by describing the underlying inflammatory profiles of the previously described recovery clusters at 5 months after hospital discharge.
The Post-hospitalisation COVID-19 study (PHOSP-COVID) is a prospective, longitudinal cohort study recruiting adults (aged ≥18 years) discharged from hospital with COVID-19 across the UK. Recovery was assessed using patient-reported outcome measures, physical performance, and organ function at 5 months and 1 year after hospital discharge, and stratified by both patient-perceived recovery and recovery cluster. Hierarchical logistic regression modelling was performed for patient-perceived recovery at 1 year. Cluster analysis was done using the clustering large applications k-medoids approach using clinical outcomes at 5 months. Inflammatory protein profiling was analysed from plasma at the 5-month visit. This study is registered on the ISRCTN Registry, ISRCTN10980107, and recruitment is ongoing.
Citation impact
- FWCI
- 49.88
- Percentile
- 100%
- References
- 42
Authors
1006Topics & keywords
- Medicine
- Observational study
- Prospective cohort study
- Logistic regression
- Emergency medicine
- Psychological intervention
- Coronavirus disease 2019 (COVID-19)
- Cluster (spacecraft)
- Good health and well-being
Funding
- ATAmerican Thoracic Society
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- GGlaxoSmithKlineAwards: C17-1, NIHR300669
- SSanofi
- GSGilead SciencesAward: COVID-19
- BBiogen
- CCelgene
- EREuropean Respiratory Society
- SLSouth London and Maudsley NHS Foundation Trust
- WTWellcome TrustAwards: CS-2016-16-020, 216606/Z/19/Z, 209553/Z/17/Z
- NINational Institute for Health and Care Excellence
- JPJazz Pharmaceuticals
- BABritish Association for Behavioural and Cognitive Psychotherapies
- MDMuscular Dystrophy UK
- LLifeArc
- URUK Research and InnovationAward: MR/V027859/1
- MMylan
- GGalecto
- CTCarrick Therapeutics
- NINational Institute for Health Research Health Protection Research Unit
- VVeracyte
- IInsmed
- NINational Institute for Health and Care Research
- BHBritish Heart Foundation
- DODepartment of Health and Social CareAward: COV0319
- RSRoyal Society
- KRKidney Research UK
- CFCystic Fibrosis Trust
- BLBritish Lung Foundation
- DUDiabetes UK
- AAAsthma and Lung UK
- RSRoyal Society of Tropical Medicine and Hygiene
- ECEuropean CommissionAward: COVID-19
- ICIntensive Care Society
- PHPublic Health England
- ARAlzheimer’s Research UK
- NNNovo Nordisk
- DPDaewoong Pharmaceutical Company
- VAVersus Arthritis
- SSeqirus
- GGenentech
- NPNovartis Pharmaceuticals UK Limited
- IEImperial Experimental Cancer Medicine CentreAward: C18616/A25153
- MRMedical Research CouncilAwards: MR/V040162/1, MR/M008894/1, MC_PC_20002, MR/S004041/1, MC_PC_19026, MC_PC_15005, MR/N029488/1, MR/T005580/1, MR/V034243/1, COVID-19, MR/J002739/1, MC_UU_00008/5
- UCUniversity College London Hospitals Biomedical Research Centre
- NLNIHR Leicester Biomedical Research Centre
- EAEuropean and Developing Countries Clinical Trials Partnership